Marvel Biosciences Corp (MRVL : TSX-V)
Common Stock
$0.17
CAD
-0.04 (-18.60%)
Last updated: 2026-06-17
MRVL
Marvel Biosciences Corp
WealthAwesomePerformance
1 Day
-18.60%
1 Week
-2.78%
1 Month
+9.37%
YTD
+29.63%
Key Statistics
Market Cap
$12.61M
52W High
$0.40
52W Low
$0.12
P/E Ratio
-
50 Day MA
$0.17
200 Day MA
$0.17
Beta
0.59
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/17/2026 | $0.21 | $0.21 | $0.17 | $0.17 | $0.17 | 169,407 |
| 6/16/2026 | $0.20 | $0.21 | $0.20 | $0.21 | $0.21 | 44,702 |
| 6/15/2026 | $0.21 | $0.23 | $0.19 | $0.20 | $0.20 | 157,780 |
| 6/12/2026 | $0.19 | $0.22 | $0.19 | $0.21 | $0.21 | 77,941 |
| 6/11/2026 | $0.18 | $0.18 | $0.18 | $0.18 | $0.18 | 27,815 |
| 6/10/2026 | $0.19 | $0.19 | $0.15 | $0.18 | $0.18 | 163,720 |
| 6/9/2026 | $0.21 | $0.21 | $0.19 | $0.20 | $0.20 | 51,964 |
| 6/8/2026 | $0.23 | $0.24 | $0.20 | $0.20 | $0.20 | 322,315 |
| 6/5/2026 | $0.20 | $0.24 | $0.19 | $0.20 | $0.20 | 294,056 |
| 6/4/2026 | $0.24 | $0.24 | $0.20 | $0.24 | $0.24 | 239,162 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRVL's historical volatility
30-Day Vol
194.7%
Annualized
90-Day Vol
141.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.21
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.19 | C$0.09 – C$0.36 |
| 60 trading days | C$0.20 | C$0.08 – C$0.51 |
| 90 trading days | C$0.21 | C$0.07 – C$0.67 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.19M
- Profit Margin
- 0.00%
- ROE (TTM)
- -380.30%
- EPS (Diluted)
- -0.04
- Book Value
- -0.07
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MRVL
Articles Featuring MRVL.V
Latest articles and analysis covering MRVL.V
